A detailed history of Balyasny Asset Management LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 101,852 shares of ARWR stock, worth $1.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
101,852
Holding current value
$1.93 Million
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.36 - $29.54 $1.97 Million - $3.01 Million
101,852 New
101,852 $1.97 Million
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $6.4 Million - $10.4 Million
270,408 Added 5026.17%
275,788 $7.01 Million
Q4 2022

Feb 14, 2023

SELL
$28.0 - $40.56 $4.77 Million - $6.91 Million
-170,303 Reduced 96.94%
5,380 $218,000
Q3 2022

Nov 14, 2022

SELL
$29.63 - $48.31 $15,140 - $24,686
-511 Reduced 0.29%
175,683 $5.81 Million
Q2 2022

Aug 15, 2022

BUY
$27.79 - $50.61 $4.34 Million - $7.9 Million
156,013 Added 773.07%
176,194 $6.2 Million
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $393,188 - $694,382
9,924 Added 96.75%
20,181 $928,000
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $5 Million - $7.1 Million
-86,013 Reduced 89.35%
10,257 $680,000
Q3 2021

Nov 15, 2021

BUY
$58.38 - $84.96 $5.62 Million - $8.18 Million
96,270 New
96,270 $6.01 Million
Q1 2021

May 17, 2021

SELL
$61.35 - $90.47 $2.12 Million - $3.13 Million
-34,543 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$43.82 - $85.37 $1.51 Million - $2.95 Million
34,543 New
34,543 $2.65 Million
Q1 2020

May 15, 2020

SELL
$20.56 - $63.12 $217,442 - $667,557
-10,576 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$28.14 - $73.01 $297,608 - $772,153
10,576 New
10,576 $671,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.